Edwards vs Abbott TAVR Showdown: One-Year Data Reveal Key Differences in Intra-Annular Valve Performance

Two Giants Kick Off the Valve Domination Race

In the field of cardiovascular disease treatment, transcatheter aortic valve replacement (TAVR) has become a highly regarded frontier technology in recent years.Surgery has brought new hope to many patients with aortic valve stenosis. In the TAVR valve market, products from the two medical giants, Edwards Lifesciences and Abbott, have been receiving considerable attention. Recently,Published inJACC: Cardiovascular InterventionsNewThe data also provided a detailed comparison of the clinical outcomes one year after the TAVR valve procedures for these two giants within the ring, as if a thrilling "Valve Showdown" had officially begun.

Edwards Lifesciences is a veteran presence in the cardiovascular medical device field. Since its founder, Miles Lowell Edwards, developed the world's first artificial heart valve in 1958, the company has continued to deepen its expertise in heart valve technology. Its SAPIEN series of TAVR valves are widely used globally and represent balloon-expandable TAVR valves, with both technological maturity and extensive clinical application experience. Abbott is equally formidable; following its acquisition of St. Jude Medical in 2017, it rapidly rose to prominence in the cardiovascular sector, with operations spanning key areas such as vascular care, rhythm management, and heart failure. Its Navitor TAVR valve, a strong competitor among self-expanding valves, also holds a significant position in the market.

This research on intra-annular TAVR valves is like a fair "competition," comparing the two on the same playing field.The intra-annular TAVR valve has a unique design, as it is positioned within the patient's native aortic annulus, which is fundamentally different from traditional valves located above the annulus. This innovative design brings new possibilities for patient treatment and also makes the comparison between the products of these two giants even more compelling.

Intra-annular TAVR Valve: The Innovative Heart Guardian

Before delving into Edwards Lifesciences' Sapien 3 Ultra TAVR valve and Abbott's Navitor TAVR valve, let’s first get to know their unique "dwelling" — the intra-annular TAVR valve. This is no ordinary "living environment"; its design represents a significant innovation in the field of cardiovascular treatment.

Traditional supra - annular valves are like devices "externally mounted" above the valve annulus, fixed near the annulus in a specific way to replace the function of the diseased aortic valve. However, intra - annular TAVR valves take a different approach, choosing to "reside" within the patient's native aortic annulus. This design difference is akin to traditional valves being like sheds built next to a house, while intra - annular TAVR valves directly move into the house itself, achieving a closer integration with the native aortic annulus.

In terms of working principle, the intra-annular TAVR valve is like a "smart repairer." Once it is accurately placed within the native aortic annulus, it self-adaptively adjusts its state according to the shape and size of the native aortic annulus. Its stent structure firmly adheres to the aortic annulus wall, acting as a "custom-made armor" for the aortic annulus, providing stable support for the valve. Meanwhile, the internal leaflet tissue functions like a precise "one-way valve," accurately controlling the unidirectional flow of blood during the heart's contraction and relaxation, preventing blood backflow, and restoring normal hemodynamic function of the aortic valve. In contrast, traditional supra-annular valves are somewhat inferior in terms of integration with native structures, operating more like an "outsider" performing a task.

The advantages of TAVR valves within the ring are also very obvious.This design, which closely fits the native aortic annulus, can better simulate the physiological function and hemodynamic characteristics of the human body's natural valve.When blood flows through the valve, it can do so more smoothly, reducing turbulence and energy loss, and lowering the risk of thrombosis, just like a once rugged road being smoothed and widened, allowing vehicles to travel more smoothly and efficiently.In terms of long-term outcomes, the intra-annular TAVR valve effectively reduces damage to surrounding tissues, lowers the probability of complications, and provides patients with more durable and stable treatment results, significantly improving their quality of life.It can be said that the intra-annular TAVR valve offers a higher quality and more physiologically suitable treatment option for patients with aortic stenosis, serving as a strong guardian of heart health. Precisely because of this, it has become the focal point of the comparative study between the two major giants, Edwards Lifesciences and Abbott, carrying the hopes of many patients and healthcare professionals.

Two Valves, Competing in the Critical Data Battlefield

In this "competition" among intra-annular TAVR valves, data serves as the most powerful "referee," clearly showcasing the performance of Edwards Lifesciences' Sapien 3 Ultra TAVR valve and Abbott's Navitor TAVR valve across various aspects. Let’s now delve into these key data points to see how the two valves fiercely compete across different dimensions.

(1) Patient Baseline: Subtle Differences

In this comparative study, the baseline characteristics of the patients are like the physical condition of the contestants before the competition. Although they may seem insignificant, they could have a subtle impact on the final outcome.Patients treated with Navitor were slightly older on average compared to those with Sapien 3 Ultra. Although the age difference was small, age is often associated with physical decline, and older patients tend to have weaker organ function, which may affect surgical tolerance and postoperative recovery. In terms of gender distribution, the Navitor group had a higher proportion of females. Differences in physiological structure and hormone levels between women and men may lead to different responses of the cardiovascular system to surgery and valve implantation.For example, women's blood vessels are generally thinner, which may increase the risk of vascular complications during surgical procedures. Additionally, the female immune system response can also affect the postoperative recovery process. The Navitor group had a higher predicted risk of death score from the Thoracic Surgeons Association, indicating that the patients in this group had more complex and severe conditions, with more comorbidities and relatively greater surgical risks. These differences in baseline characteristics are like setting some small "obstacles" for the Navitor group in a competition. When analyzing the performance of the two valves subsequently, these factors need to be fully taken into account.

(II) Surgery-related: Success or Failure and Length of Hospital Stay

The various data during the surgical process are important indicators to measure the performance of the valve, just like the technical statistics in a sports game, which can intuitively reflect the "strength" of the valve during the surgery.Navitor's device success rate is as high as 91.2%, while Sapien 3 Ultra's is 87%. Navitor has a slight edge in this aspect.Successful device implantation is a critical step in the success of the surgery. A high success rate indicates that, in most cases, Navitor can be more smoothly placed in the appropriate position and function properly. However, the success of the surgery depends not only on device implantation but also on factors such as postoperative complications and length of hospital stay.In terms of surgical complications, the average hospital stay for patients receiving the Navitor valve was significantly longer at 4 days, compared to 3.4 days for Sapien 3 Ultra patients.A longer hospital stay not only increases the financial burden and psychological stress on patients but may also indicate a less smooth postoperative recovery process, with some underlying issues requiring extended observation and treatment. Moreover, the Navitor group exhibited higher rates of new-onset left bundle branch block and new permanent pacemaker implantation (PPI), complications that could affect normal cardiac electrophysiological activity and have long-term impacts on heart function. In contrast, the Sapien 3 Ultra demonstrated certain advantages in terms of hospital stay duration and the incidence of specific complications, forming a stark contrast to Navitor in overall surgical performance.

(III) Clinical Outcomes: The Battle Between Short-term and Long-term

Clinical outcomes are the core indicators for evaluating the effectiveness of valve treatments, akin to the final score of a game, directly reflecting the long-term impact of the valve on a patient's health condition.At the 30-day short-term observation point, there were no significant differences in all-cause mortality, stroke, or repeat hospitalization for heart failure between the two valves post-treatment. This indicates that in the early postoperative period, both valves performed similarly in safeguarding patient survival and preventing major adverse events. However, some differences emerged after one year. Among patients treated with the Navitor valve, 4.6% experienced heart failure hospitalization, compared to 2.8% for those treated with the Sapien 3 Ultra.Heart failure is a manifestation of severe impairment of cardiac function, and a higher hospitalization rate for heart failure suggests that patients in the Navitor group may experience more cardiac function issues during long-term treatment. From this long-term outcome, the Sapien 3 Ultra appears to have an advantage in preventing heart failure, offering more stable protection of cardiac function for patients. However, this does not mean that the Navitor is completely at a disadvantage. Clinical outcomes are influenced by various factors, and a comprehensive evaluation of the value of the two valves requires consideration of performance in other aspects.

(4) Echocardiography: In-depth Analysis of Valve Function

Echocardiogram data are like slow-motion replays in a game, offering an in-depth view of how the valves work inside the heart and revealing differences in their functionality. The Sapien 3 Ultra TAVR valve has consistently been associated with a lower rate of paravalvular leakage. Paravalvular leakage refers to blood leaking between the prosthetic valve and the native annulus, which not only reduces the heart's pumping efficiency but also can lead to severe consequences such as cardiac enlargement and heart failure if it persists long-term. A lower rate of paravalvular leakage indicates that the Sapien 3 Ultra performs exceptionally well in terms of its fit with the native annulus and sealing capabilities, better maintaining normal cardiac hemodynamics. However, the Sapien 3 Ultra does have certain characteristics: it is associated with higher residual transprosthetic gradients and larger effective orifice areas. Higher residual transprosthetic gradients mean that blood passing through the valve needs to overcome greater resistance, potentially increasing the heart’s workload; whereas a larger effective orifice area suggests that the valve allows smoother blood flow, enhancing the heart’s pumping capacity. In comparison,The Navitor valve shows differences from the Sapien 3 Ultra in terms of paravalvular leak rate, residual transprosthetic gradient, and effective orifice area. These differences reflect distinctions in design and operating principles between the two valves, providing important reference points for doctors to select the appropriate valve based on specific patient conditions.

Clinical Insights and Future Perspectives: Exploring New Directions in Cardiovascular Therapy

This "competition" of intra-annular TAVR valves provides valuable reference for clinical practice.Sapien 3 Ultra Shows Excellent Performance in Paravalvular Leak ControlFor patients with relatively fragile perivalvular tissue and a higher risk of paravalvular leakage, Sapien 3 Ultra might be a better choice. A lower rate of paravalvular leakage can reduce blood regurgitation, alleviate the burden on the heart, and facilitate postoperative cardiac function recovery. Although Navitor performs slightly worse in terms of paravalvular leakage, its advantage in device success rate should not be overlooked. For some patients with greater surgical difficulty and higher requirements for device implantation success rates, Navitor may offer more reliable assurance. However, the higher incidence of new-onset left bundle branch block and new permanent pacemaker implantation in the Navitor group, along with longer hospital stays, also remind doctors to comprehensively consider the patient's cardiac electrophysiological condition and overall recovery capacity when making a choice.

In the long run, the development prospect of TAVR valve technology is broad. With the continuous advancement of technology, future TAVR valves may achieve greater breakthroughs in materials, design, and functionality. In terms of materials, the development of more durable and biocompatible materials can effectively extend the service life of the valve and reduce the risk of secondary surgery. Just like modern smartphones, new materials and technologies are applied periodically, making phones lighter, thinner, more durable, and with stronger performance. The future TAVR valve might be the same, with new materials perhaps performing like superelastic memory alloys, maintaining stable performance in the complex heart environment. In terms of design, there may be more personalized designs, customizing valves based on each patient’s aortic annulus shape, size, and cardiac physiological characteristics. This is similar to tailoring a high-end suit that perfectly fits the body curve, offering more comfort and style. Personalized valve designs will better adapt to individual differences among patients, further improving treatment outcomes and quality of life. Functionally, the valve may possess more intelligent features, such as real-time monitoring of heart function and valve status, transmitting data to doctors for timely problem detection and treatment adjustment. Imagine the valve acting like a smart health bracelet, constantly monitoring heart health and safeguarding the patient's cardiac well-being. The future of TAVR valve technology is full of infinite possibilities, continuing to bring more hope to cardiovascular disease patients and becoming a powerful tool in protecting heart health.

Reference:

Stefano Cannata, Ibrahim Sultan, Nicolas Van Mieghem, et al. Transcatheter Aortic Valve Replacement With Intra-Annular Self-Expanding or Balloon-Expandable Valves: The Multicenter International NAVULTRA Registry. J Am Coll Cardiol Intv. May 10, 2025.